Lexicon Pharmaceuticals (LXRX, Financial) experienced a significant stock price decline of 5.24%. The stock is currently trading at $0.835 per share with a trading volume of 1.37 million shares and a turnover rate of 0.38%. The stock's price volatility is marked by a 6.29% amplitude.
Recent financial reports reveal that Lexicon Pharmaceuticals generated a revenue of $1.75 million, with a net loss of $64.81 million and an earnings per share (EPS) of -$0.18. The company's gross profit stood at $1.55 million, resulting in a price-to-earnings (P/E) ratio of -1.13.
In terms of analyst ratings, out of five institutions covering the stock, 60% recommend buying, while 40% suggest holding. None have issued a sell recommendation.
Within the biotechnology sector, which saw an overall increase of 0.34%, several stocks showed notable performance. Forte Biosciences, Inc., Klotho Neurosciences Inc, and NLS Pharmaceutics Ltd exhibited significant gains. Forte Biosciences, Inc., Silexion Therapeutics Corp, and Exicure, Inc. were highly active, with turnover rates of 1778.34%, 1265.61%, and 937.86% respectively. Stocks with large price swings included Klotho Neurosciences Inc, Forte Biosciences, Inc., and Exicure, Inc., with amplitudes of 185.64%, 169.09%, and 136.94% respectively.
Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products for human diseases. Its pipeline includes LX9211, an oral small molecule for neuropathic pain, and sotagliflozin, an oral small molecule for heart failure and type 1 diabetes.
